LAURUSLABS Share Price Performance
₹857.50
434.70 (102.81%)
0.3% undervalued intrinsic discount
₹860.00
Fair Value
Price ₹857.50
AnalystHighTarget ₹860.00
AnalystConsensusTarget ₹698.46
AnalystLowTarget ₹305.61
Fair Value₹860.00
Share Price₹857.50
0.3% undervalued intrinsic discount
LAURUSLABS Community Narratives
AN
Fair Value ₹860.00 0.3% undervalued intrinsic discount
Expanding CDMO Pipeline Will Tap Global Secular Demand
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value ₹698.46 22.8% overvalued intrinsic discount
Global Healthcare Growth Will Spur CDMO Expansion While Tempering Risks
0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
AN
Fair Value ₹305.61 180.6% overvalued intrinsic discount
Rising Regulation And Competition Will Weaken Prospects Despite CDMO Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
LAURUSLABS Community Fair Values
- ₹698.46FV22.8% overvalued intrinsic discount13.99%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative13users have followed this narrativeUpdated narrative
- ₹305.61FV180.6% overvalued intrinsic discount13.45%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrative13 days ago author updated this narrative
- ₹860.00FV0.3% undervalued intrinsic discount17.92%Revenue growth p.a.0users have liked this narrative0users have commented on this narrative0users have followed this narrative13 days ago author updated this narrative
Recent LAURUSLABS News & Updates
No updates
Laurus Labs Limited Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 9.43
- Gross Margin
- 54.64%
- Net Profit Margin
- 8.58%
- Debt/Equity Ratio
- 60.0%
Laurus Labs Limited Competitors
About LAURUSLABS
- Founded
- 2005
- Employees
- 6167
- CEO
- WebsiteView website
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and oral solid formulations for advanced intermediates for anti-retroviral (ARV), antidiabetic, cardiovascular, anti-asthma, ophthalmology, oncology, gastroenterology, and hepatitis C therapeutic areas. It also provides biotechnology services used in the nutraceutical, dietary supplements, alternate food proteins, and cosmeceutical products. In addition, the company develops novel enzymatic solutions for industrial biotechnology, and animal origin free recombinant proteins and enzymes for biopharma; and offers business support services for pharmaceuticals field. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
Indian Market Performance
- 7 Days: 0.2%
- 3 Months: 5.2%
- 1 Year: -2.4%
- Year to Date: -1.1%
The market has been flat over the last week. In line with that, the market has also been flat over the past year. Earnings are forecast to grow by 15% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading